Health2047 and its services

Health2047 is a health tech business enterprise started by AMA to tackle the problems with the raising problems with healthcare. Health2047 was launched in 2016, during the 34th annual JP Morgan conference. The head office of the firm is based in Menlo Park California. The firm aims to bring change in the $3trillion healthcare system to a system level by developing and commercializing solutions for the significant growing health problem. The firm has identified four major increasing issues in the United States that is data liquidity, chronic diseases, productivity, and healthcare value.

Health2047 is focusing on the identified problems chronic diseases, data liquidity, productivity and healthcare values. The problems with data liquidity are one of the raising problems that is affecting the healthcare sector. The physicians are not able to pay more time to their patients as most of the time is spent with documentation and finding files. To improve data liquidity in healthcare, the firm has started a new started by investing $10 million. The new firm is known as Akiri Switch formerly known as Switch Co. the firm is committed to creating a secured network for data exchange among the patients and physicians.

Health2047 has been working on chronic diseases. Chronic diseases include heart attack, diabetes, blood pressures, strokes and much more. To control diabetes 2, health2047 has launched a new firm known as the First Mile Care. First Mile Care is providing training to the pre-diabetes patients about how to avoid diabetes 2. Health2047 started First Mile Care in October 2018 with the initial investment of $ 2 million.

Health2047 is providing a unique platform for doctors to participate and share ideas with the fellows from the healthcare industry as well as the technology sector. They are offered more opportunities to get involved in the innovation process. Health2047 is creating solutions and equipment and trying to commercialize those solutions.

Health2047 has tried to bring change in the healthcare industry, but with the support from another sector, it was neither possible nor easy. The firm has collaborated with technology sector to bridge the gap in the healthcare setting.

The article illustrates health2047. It goes through the areas they are focusing on bringing change.

Board of directors at health2047

Health2047 consist of highly specialized physicians how to have more than ten years of experiences in healthcare.

James Madara:

Dr. James Madara serves as the CEO of the American Medical Association. Jim has valuable experience of addressing strategic, operational and financial challenges at leading medical and biosciences organizations. Jim is passionate about creating a healthcare system that delivers better outcomes for all.

Before joining AMA in 2011, Jim was a CEO of the medical center at the University of Chicago. He has also served as Timmie Professor and chair of the department of pathology and laboratory medicine at Emory University, and professor of pathology at Harvard Medical School. Jim holds a BA from Juniata College, an MD from Hahnemann Medical School, and an honorary MA from Harvard University.

Elizabeth Ronn

Elizabeth serves as Independent Board Director at Health2047 Inc. She is well known for marketing/branding expert, entrepreneur, advisor, and passionate advocate of mission-driven innovation. She co-founded a health and wellness company and is a partner at innovation consulting firm Innofolio. Elizabeth has more than 20 marketing experience at Procter & Gamble, and she was a Vice President of Marketing. Elizabeth holds her BA in Economics, with honors, from Louisiana State University and her MBA from Stanford University. Elizabeth also serves on the board of trustees for the San Francisco Art Institute, is Chair of the Governance Council of WANDA.

Lawrence K. Cohen,

Larry is the CEO of Health2047 Inc. he is an experienced biotechnology leader, and he thrives in the development of drugs and platforms to treat illnesses. Larry has also served as Executive Vice President of Research and Business Development at Kadmon Holdings. He has also served as a President and CEO of San Francisco’s VIA Pharmaceuticals, where he spearheaded efforts to develop small-molecule drugs to treat cardiovascular diseases. He was President and CEO of Fremont-based proteomics company Zyomyx; COO of Menlo Park-based Progenitor, Inc. He earned a Ph.D. degree in Microbiology from the University of Illinois and completed his postdoctoral work in Molecular Biology at the Dana-Farber Cancer Institute and the Department of Biochemistry at Harvard Medical School. He earned his B.A. from Grinnell College.

This article put a light on the boards of directors at health2047. The BOD also includes Ken Sharigian, Ray Bingham, Jesse Ehrenfeld, and Doug Given.